Cuprina Holdings Notified by Nasdaq on Minimum Bid Price Shortfall

Posted on by

SINGAPORE, Nov. 28, 2025 — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR), also referred to as “Cuprina” or “the Company,” which is focused on developing and selling products in the chronic wound, infertility, and cosmeceutical markets, has been notified by Nasdaq on November 26, 2025, that it is no longer in compliance with Nasdaq Listing Rule 5550(a)(2). The rule requires a minimum bid price of $1 per share, which Cuprina has failed to maintain over the past 30 consecutive business days.

However, under Nasdaq Listing Rule 5810(c)(3)(A), Cuprina has 180 calendar days to regain compliance. If the company’s closing bid price is at least $1 for a minimum of ten consecutive business days during this period, Nasdaq will confirm compliance in writing, and the matter will be closed.

If Cuprina fails to regain compliance within the initial period, it may be eligible for an extension if it meets the requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (except the bid price). The company must also provide written notice of its intent to correct the deficiency during the second compliance period, possibly through a reverse stock split. If these requirements are met, Nasdaq may grant an additional 180 calendar days. However, if Nasdaq believes the company cannot cure the deficiency, or if Cuprina is otherwise ineligible, Nasdaq will issue a delisting notice.

The Nasdaq notification does not immediately delist Cuprina’s ordinary shares, which will continue to trade on the exchange under the symbol “CUPR.”

Cuprina is currently exploring options to regain compliance with Nasdaq’s continued listing requirements and intends to do so in a timely manner. While Cuprina will make reasonable efforts to comply with Rule 5550(a)(2), there is no guarantee that it will be able to regain compliance or maintain compliance with other Nasdaq continued listing requirements.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company focused on developing and commercializing innovative products for chronic wound management and operating in the health and beauty sectors. Our biomedical research expertise allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices that meet international standards. For more information, please visit https:// .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements regarding future expectations, plans, and prospects, including statements about expected trading commencement and closing dates. These statements, identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, are subject to risks and uncertainties that could cause actual results to differ materially. These factors include uncertainties related to market conditions, the completion of the public offering, and other risks detailed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. Investors should not place undue reliance on these forward-looking statements, which are based on information available as of the date of this release. Cuprina Holdings (Cayman) Limited disclaims any obligation to update these statements, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email:

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email:

“`